GENFIT Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH Post author:Sam Post published:June 22, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017 Star R&D Duo Nabs $65 Million for Iterum to Develop Shelved Pfizer Antibiotic May 18, 2017 Pressure BioSciences, Inc. Achieves CE Marking For Its Next Generation Sample Preparation Instrument, The Barocycler 2320EXTREME February 1, 2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017
Pressure BioSciences, Inc. Achieves CE Marking For Its Next Generation Sample Preparation Instrument, The Barocycler 2320EXTREME February 1, 2017